Ligand Pharma (LGDN) Stock Statistics & Valuation Metrics

Ligand Pharma has a market cap or net worth of CHF4.52B. The enterprise value is CHF6.68K.

Ligand Pharma has 19,935,610 shares outstanding. The number of shares has decreased by -2.65% in one year.

Ligand Pharma’s return on equity (ROE) is 0.12 and return on invested capital (ROIC) is 2.42%.

The current PE Ratio of Ligand Pharma is 28.8. Ligand Pharma’s PEG ratio is -0.00970.

In the last 12 months, Ligand Pharma had revenue of 268.09M and earned 124.45M in profits. Earnings per share was 6.44.

In the last 12 months, operating cash flow was 131.64M and capital expenditures -278.00K, giving a free cash flow of 131.37M billion.

Ligand Pharma pays an annual dividend of ―, resulting in a dividend yield of ―

Ligand Pharma upcoming earnings date is Nov 5, 2026, After Close (Confirmed).

Ligand Pharma as a current ratio of 22.23, with Debt / Equity ratio of 116.94%

In the past 12 months, Ligand Pharma has paid 34.51M in taxes.

Ligand Pharma EV to EBITDA ratio is 20.41, with an EV/FCF ratio of 80.41.

Ligand Pharma has CHF1.36B in cash and marketable securities with CHF1.13B in debt, giving a net cash position of CHF226.31M billion.

Gross margin is 98.58%, with operating margin of 17.61%, and net profit margin of 46.42%.

The average price target for Ligand Pharma is CHF284.84, which is 11.43% higher than the current price. The consensus rating is Strong Buy